Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Full-spectrum intelligence on one of Korea’s most clinically active stem cell companies.
This report provides a complete, non-simplified due diligence dossier on CHA Biotech, a flagship regenerative medicine subsidiary of CHA Medical Group.
85+ Patents Mapped: From NK cell immunotherapies to conditioned stem cell media, each major patent is dissected with cross-border IP strength, clinical usage, and citation analytics.
Full Clinical Pipeline Breakdown: Includes all trials (past & present) with strategic value mapping — from JointSTEM (approved) to pre-IND neurodegenerative programs.
Financial Control Layer: Deep-dive into revenue, burn rate, and R&D trends. We link operating loss with scalability investments, not structural fragility.
Governance & Ownership Matrix: 21 subsidiaries analyzed, including CDMO, Cosmeceuticals, and Vaccine branches.
Auditor Risk Flags: No "going concern" issues; internal controls clean (ref: page 104, 2025.03.31 audit report).
Red Flag Filter: Cancelled, suspended, or failed clinical assets clearly segregated and interpreted.
VCs, family offices, and strategic buyers often underestimate hybrid hospital-biotech structures like CHA Biotech. This report decodes the real defensibility: verticalized infrastructure, export-ready platforms, and IND-aligned IP families.
Access Password
This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.
🔐 Example: 6 digit
If you encounter any issues, contact us at yoonhwa.an@biopharmabusinessintelligenceunit.com
Full-spectrum intelligence on one of Korea’s most clinically active stem cell companies.
This report provides a complete, non-simplified due diligence dossier on CHA Biotech, a flagship regenerative medicine subsidiary of CHA Medical Group.
85+ Patents Mapped: From NK cell immunotherapies to conditioned stem cell media, each major patent is dissected with cross-border IP strength, clinical usage, and citation analytics.
Full Clinical Pipeline Breakdown: Includes all trials (past & present) with strategic value mapping — from JointSTEM (approved) to pre-IND neurodegenerative programs.
Financial Control Layer: Deep-dive into revenue, burn rate, and R&D trends. We link operating loss with scalability investments, not structural fragility.
Governance & Ownership Matrix: 21 subsidiaries analyzed, including CDMO, Cosmeceuticals, and Vaccine branches.
Auditor Risk Flags: No "going concern" issues; internal controls clean (ref: page 104, 2025.03.31 audit report).
Red Flag Filter: Cancelled, suspended, or failed clinical assets clearly segregated and interpreted.
VCs, family offices, and strategic buyers often underestimate hybrid hospital-biotech structures like CHA Biotech. This report decodes the real defensibility: verticalized infrastructure, export-ready platforms, and IND-aligned IP families.
Access Password
This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.
🔐 Example: 6 digit
If you encounter any issues, contact us at yoonhwa.an@biopharmabusinessintelligenceunit.com